Stoke Therapeutics, Inc.
STOK
$31.36
-$1.13-3.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 344.29% | -86.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 344.29% | -86.81% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 344.29% | -86.81% | |||
| SG&A Expenses | -5.54% | 31.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.08% | 16.97% | |||
| Operating Income | 13.06% | -42.58% | |||
| Income Before Tax | 13.69% | -46.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.69% | -51.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.69% | -51.08% | |||
| EBIT | 13.06% | -42.58% | |||
| EBITDA | 13.20% | -43.11% | |||
| EPS Basic | 15.09% | -42.72% | |||
| Normalized Basic EPS | 15.08% | -38.13% | |||
| EPS Diluted | 15.51% | -43.44% | |||
| Normalized Diluted EPS | 15.08% | -38.13% | |||
| Average Basic Shares Outstanding | 1.65% | 5.85% | |||
| Average Diluted Shares Outstanding | 1.65% | 5.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||